Esketamine, administered nasally under supervision, was highlighted for its
A panel of psychiatrists reviewed treatment pathways for treatment-resistant depression on October 5, 2026, focusing on structured care levels and neuromodulation techniques. The discussion took place during a virtual symposium hosted by a leading mental health institute, where experts evaluated inpatient, partial hospitalization, and intensive outpatient programs as foundational steps before considering advanced interventions. The goal was to clarify when and how electroconvulsive therapy, transcranial magnetic stimulation, and esketamine should be integrated into patient care plans based on clinical severity and response history. The experts emphasized that structured programs provide essential stabilization, allowing clinicians to assess true treatment resistance before moving to device-based or pharmacological interventions. Electroconvulsive therapy remains the most effective option for severe, urgent cases, particularly when psychosis or catatonia is present, while transcranial magnetic stimulation offers a non-invasive alternative for moderate resistance with fewer cognitive side effects.
Wellness insights
What Counselling in Two Different Countries Taught Me: Hansel Wong on Connection, Curiosity, and Culture
Dr. LaNail Plummer Shares Insights on Starting Therapy
GH001 Shows Rapid Relief for Postpartum Depression in Early Trial
Coping with a Breast Cancer Diagnosis: How to Support Your Loved OneEsketamine, administered nasally under supervision, was highlighted for its rapid onset in suicidal ideation, though concerns about dissociation and abuse potential require careful patient selection and monitoring. How Do Patient Preferences Influence Treatment Selection Patient values and lifestyle factors play a critical role in choosing between ECT, TMS, and esketamine, according to the panel. Some individuals avoid ECT due to stigma or fear of memory effects, opting instead for TMS despite its longer treatment course. Others prefer esketamine for its convenience compared to frequent clinic visits, though adherence depends on support systems and insurance coverage. The psychiatrists stressed that shared decision-making improves outcomes by aligning interventions with individual priorities and tolerances. What Are the Risks of Combining These Therapies Combining neuromodulation treatments requires caution due to overlapping effects on brain excitability and limited safety data.
The experts noted that while sequential use—such as TMS after incomplete ECT
The experts noted that while sequential use—such as TMS after incomplete ECT response—is common, concurrent administration increases seizure risk and is not recommended without rigorous monitoring. Esketamine should not be administered within 24 hours of ECT due to potential cardiovascular strain, and clinicians must adjust dosing when combining with antidepressants to avoid serotonin syndrome or heightened dissociation. Long-term management of treatment-resistant depression depends on maintaining gains from acute interventions through psychotherapy, lifestyle support, and relapse prevention strategies. The panel warned that without continuity of care, remission rates drop significantly within six months, underscoring the need for integrated models that bridge acute treatment with sustained recovery. Future research should focus on identifying biomarkers to predict response and personalize sequencing of these interventional options. Frequently Asked Questions Is ECT still considered safe for older adults?
Yes, ECT remains safe and effective for elderly patients when cardiac and metabolic risks are pre-screened and managed, with modified techniques reducing cognitive side effects. Can TMS be used if a patient has metal implants in the head? TMS is contraindicated near ferromagnetic implants such as aneurysm clips or cochlear implants due to risks of displacement or heating, but may be safe with titanium or plastic devices at a distance. How often can esketamine be administered without increasing abuse risk? Esketamine is typically limited to twice weekly during induction phase, then weekly or biweekly during maintenance, with strict supervision and screening for misuse patterns.
